Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis

@article{Moujalled2016AdvancesIT,
  title={Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis},
  author={Diane Moujalled and A. White},
  journal={CNS Drugs},
  year={2016},
  volume={30},
  pages={227-243}
}
  • Diane Moujalled, A. White
  • Published 2016
  • Medicine
  • CNS Drugs
  • AbstractAmyotrophic lateral sclerosis (ALS) is a progressive adult-onset, neurodegenerative disease characterized by the degeneration of upper and lower motor neurons. Over recent years, numerous genes ha ve been identified that promote disease pathology, including SOD1, TARDBP, and the expanded hexanucleotide repeat (GGGGCC) within C9ORF72. However, despite these major advances in identifying genes contributing to ALS pathogenesis, there remains only one currently approved therapeutic: the… CONTINUE READING
    24 Citations
    From animal models to human disease: a genetic approach for personalized medicine in ALS
    • 70
    [Dimebon delays the onset of symptoms of FUS-proteinopathy in transgenic mice].

    References

    SHOWING 1-10 OF 137 REFERENCES
    Mechanisms, models and biomarkers in amyotrophic lateral sclerosis
    • 128
    • Highly Influential
    • PDF
    Rodent Models of Amyotrophic Lateral Sclerosis
    • 107
    The non-cell-autonomous component of ALS: new in vitro models and future challenges.
    • 18
    Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
    • 404
    • PDF
    Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
    • 476
    • PDF
    Excitotoxicity and Amyotrophic Lateral Sclerosis
    • 144